Education · GLP-1 Medications
You’ve probably typed some version of this question into Google already. Maybe more than once. And you’ve likely found either a two-sentence non-answer or a deep dive into pharmacology that lost you somewhere around “incretin pathway modulation.”
This post explains what your provider is actually thinking about when choosing between these two medications — in plain language, without oversimplifying the science.
They Work Differently — and That Difference Is Clinically Meaningful
Both semaglutide and tirzepatide are GLP-1 receptor agonists. That means they both work with your body’s natural appetite and metabolic signaling system rather than forcing it into submission. But they’re not the same medication.
Semaglutide activates one receptor: the GLP-1 receptor. This receptor shows up in three key places: the brain (where it regulates fullness signals and appetite), the pancreas (where it supports healthy insulin release), and the digestive tract (where it slows gastric emptying — meaning food moves through your stomach more slowly, keeping you full longer).
Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP adds a second layer of metabolic influence — additional appetite regulation and effects on how your body stores and uses energy. Because tirzepatide engages two systems simultaneously, providers often describe it as a dual agonist.
Think of it this way: semaglutide turns down the volume on hunger through one channel. Tirzepatide turns it down through two.
What the Research Shows
Both medications have been studied in large-scale clinical trials — some of the most rigorous in the weight management literature. The findings consistently show that:
- Participants using semaglutide experienced meaningful reductions in body weight, along with improvements in metabolic markers like blood sugar and blood pressure.
- Participants using tirzepatide showed substantial weight reduction across multiple large trials, with the dual-agonist mechanism producing robust effects on both weight and metabolic health.
Without quoting specific numbers — which vary significantly based on individual factors, dose, diet, and duration — the honest summary is this: both medications are well-supported by clinical evidence. The question isn’t which one works. It’s which one is right for you specifically.
Curious whether a GLP-1 program might be appropriate for you? The eligibility form at Your Infinity Health takes about five minutes and puts your intake directly in front of a licensed provider — no commitment required.
How Providers Actually Make the Call
When a licensed provider reviews your health intake, they’re not looking at a single variable. They’re building a picture of your metabolic health, history, and goals. Here’s what typically shapes the decision:
Your metabolic profile. Patients with insulin resistance, prediabetes, or type 2 diabetes may benefit particularly from tirzepatide’s dual-receptor action, given how GIP works alongside GLP-1 in glucose metabolism. Patients without those specific factors may respond well to either medication.
Your degree of metabolic risk. Providers consider what’s at stake clinically — not just current weight, but cardiovascular risk, joint health, liver function, and the other ways excess weight affects long-term health. That informs both the medication and the appropriate dose escalation approach.
Tolerability and your medical history. Both medications can cause GI side effects, particularly nausea during the dose escalation phase. Providers consider how a patient has responded to other medications — and whether there are contraindications specific to either option.
Other health conditions and current medications. Patients managing thyroid conditions, PCOS, hormonal changes from perimenopause, or cardiovascular risk factors require careful evaluation of interactions and contraindications before any GLP-1 is prescribed. This is not a decision you should make on your own — and a good provider won’t let you.
Practical factors. Cost, injection frequency, and your own comfort with a given treatment are real considerations. A treatment you can sustain is more effective than a theoretically superior one you abandon at week six.
Important
No article — including this one — can tell you which medication is right for you. That determination belongs with a licensed provider who has reviewed your full health history, current medications, and metabolic profile.
Both Options Are Available at Your Infinity Health
Your Infinity Health offers both semaglutide and tirzepatide through its physician-supervised program. Neither is a default. The licensed provider who reviews your eligibility intake determines which option — and which starting dose — is clinically appropriate for your specific situation.
This is supervised medical care, not a subscription box. Every patient is evaluated individually. If questions come up before or during treatment, there’s a real medical team to answer them.
|
Semaglutide Program $199/mo Fixed price, any dose GLP-1 receptor agonist Physician-supervised Available all 50 states Provider review within 24h |
Tirzepatide Program $299/mo Fixed price, any dose Dual GLP-1 + GIP agonist Physician-supervised Available all 50 states Provider review within 24h |
Both programs include physician-supervised care and ongoing medical support. Final medication selection is made by the reviewing provider based on individual eligibility.
Ready to find out which option is right for you?
Start your eligibility form — it takes five minutes and is reviewed by a licensed provider within 24 hours.
Compounded medications are not FDA-approved finished products. Both semaglutide and tirzepatide available through Your Infinity Health are prepared by U.S.-licensed compounding pharmacies under individual prescriptions. All treatment decisions are made by licensed healthcare providers based on individual medical history and eligibility. Results vary. This content is for informational purposes only and does not constitute medical advice.
